clinical trial · NCT06646055
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Akeso·phase2·active not recruiting·n = 110
Metastatic Pancreatic Ductal AdenocarcinomaAK112, Cadonilimab, nab-paclitaxel, gemcitabineAK112, Cadonilimab, nab-paclitaxel, gemcitabineAK112, Cadonilimab, nab-paclitaxel, gemcitabineAK112, nab-paclitaxel, gemcitabinenab-paclitaxel, gemcitabine
brief summary
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.
started
Jan 21, 2025
primary completion
Dec 30, 2026
completion
Dec 30, 2027
last updated
Mar 9, 2026
official title
A Phase Ib/II Clinical Study of AK112 and Cadonilimab Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol